BridgeBio Oncology reports Q2 2026 results, starts two KRAS inhibitor combination trials

BridgeBio Oncology Therapeutics (Nasdaq: BBOT) reported financial results for the second quarter ended June 30, 2026, on August 11, 2026, alongside a business update on its three clinical programs targeting RAS-pathway cancers.

During the quarter, the company continued to enroll patients in a combination of BBO-8520 plus pembrolizumab in non-small cell lung cancer carrying the KRAS G12C mutation¹ and initiated a combination of BBO-8520 plus BBO-10203 in patients with G12C NSCLC¹. For its pan-KRAS inhibitor, BBOT continued enrolling BBO-11818 monotherapy across multiple dose levels and initiated dosing of BBO-11818 in combination with cetuximab¹. After the quarter ended, the company initiated dosing of BBO-11818 in combination with BBO-10203¹. For BBO-10203, the company continued to enroll patients in HR+ breast cancer, HER2+/HR- breast cancer, and colorectal cancer combination cohorts¹.

BBOT also presented preclinical data at the AACR meeting. This included data highlighting the potency of BBO-11818 in KRASG12D and KRASG12V models, combination effects with cetuximab or BBO-10203, and complete tumor regressions through adaptive immunity when combined with anti-PD-1 antibodies¹, along with findings that BBO-10203 showed a strong in vivo combination effect with the HER2 inhibitors tucatinib or trastuzumab in HER2-amplified tumor models¹.

CEO Pedro J. Beltran said the company has multiple near-term clinical milestones across all programs expected in the second half of 2026¹.

On finances, BBOT reported cash, cash equivalents and marketable securities totaling $344.1 million as of June 30, 2026, which is expected to provide cash runway into 2028¹. Net loss for the quarter was $56.5 million, compared with $28.4 million in the same period of 2025¹.